17653-93-9

Usage

Nitrile compound

Contains a cyano group (-C≡N)
A nitrile group is a functional group consisting of a carbon atom triple-bonded to a nitrogen atom, giving the compound unique chemical properties.

Intermediate in synthesis

Used in the production of pharmaceuticals and agrochemicals
As an intermediate, 2-(3-Methoxyphenyl)-2-methylpropanenitrile serves as a building block for creating more complex molecules in the synthesis of drugs and pesticides.

Building block for organic compounds

Can be used to create new compounds with specific properties and applications
The chemical structure of the compound allows it to react with other molecules, forming new organic compounds with tailored characteristics for various uses.

Potential applications in other industries

Beyond pharmaceuticals and agrochemicals
The compound may have uses in industries such as materials science, due to its unique structure and reactivity.

Proper handling and safety measures

Importance of safety when working with the compound
As with any chemical, it is crucial to follow proper handling procedures and safety precautions to minimize risks associated with the use of 2-(3-Methoxyphenyl)-2-methylpropanenitrile.

Upstream product

• 78-82-0 Isobutyronitrile 
• 456-49-5 1-fluoro-3-methoxybenzene 
• 19924-43-7 3-methoxyphenylacetonitrile 
• 586-37-8 1-(3-Methoxyphenyl)ethanone 
• 25108-57-0 3-(1-methylethenyl)anisole 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 
• 12116-44-8 (η6-anisol)tricarbonyl chromium 
• 50654-53-0 2-lithio-2-methylpropionitrile 
• 74-88-4 methyl iodide 
• 22739-77-1 2-Methylpropionitrile-d7 

Downstream Products

• 17653-94-0 α-methyl-α-(3-methoxyphenyl)proprionic acid 
• 1067192-48-6 2-(3-methoxy-4-nitrophenyl)-2-methylpropanenitrile 
• 1200397-23-4 2-(3-(2,6-dimethylbenzyloxy)phenyl)-2-methylpropanoic acid 
• 1200397-41-6 2-(3-(2,6-dimethylbenzyloxy)phenyl)-2-methylpropanenitrile 
• 1200397-42-7 2-(3-(2,6-dimethylbenzyloxy)phenyl)-2-methylpropanal 
• 1620518-38-8 2-(3-hydroxyphenyl)-1-[5-(3-hydroxyphenyl)thiophen-2-yl]-2-methylpropan-1-one 
• 1620518-37-7 2-(3-methoxyphenyl)-1-[5-(3-methoxyphenyl)thiophen-2-yl]-2-methylpropan-1-one 
• 60812-46-6 2-(3-methoxyphenyl)-2-methylpropane-1-amine 
• 184906-32-9 3,3-Dimethyl-5-(1-phenyl-1H-tetrazol-5-yloxy)-2,3dihydroisoindol-1-one 
• 184906-29-4 5-methoxy-3,3-dimethylisoindolin-1-one 
• 109138-26-3 1-(1-Isocyanato-1-methylethyl)-3-methoxybenzene 
• 184906-31-8 5-Hydroxy-3,3-dimethyl-2,3-dihydroisoindol-1-one 
• 19194-52-6 3,3-dimethylisoindolin-1-one 
• 17653-95-1 2-(3-methoxyphenyl)-2-methyl-propan-1-ol 

Relevant academic research and scientific papers

Thermodynamic Control of Regioselectivity in the Addition of Carbanions to (Arene)tricarbonylchromium Complexes

The results of a study of question of kinetic or thermodynamic control of the addition of carbon nucleophiles to (arene)Cr(CO)3 complexes are presented. 2-Lithio-2-methylpropionitrile (1) is shown to add reversibly to (naphthalene)Cr(CO)3 (2), (5,8-dimeth

Palladium-Catalyzed Distal m-C-H Functionalization of Arylacetic Acid Derivatives

Herein, we present m-C-H olefination on derivatives of phenylacetic acids by tethering with a simple nitrile-based template through palladium catalysis. Notably, the versatility of the method is evaluated with a wide range of phenylacetic acid derivatives for obtaining the meta-olefination products in fair to excellent yields with outstanding selectivities under mild conditions. Significantly, the present strategy is successfully exemplified for the synthesis of drugs/natural product analogues (naproxen, ibuprofen, paracetamol, and cholesterol).

Cobalt-catalyzed C[sbnd]H activation/C[sbnd]O formation: Synthesis of benzofuranones

Herein, C[sbnd]H activation/C[sbnd]O formation reaction using novel cobalt catalytic system is reported. This reaction was given benzofuranones in moderate to excellent yields at room-temperature under air reaction conditions. The introduced strategy is efficient and low-cost method to synthesized benzofuranones from α,α-disubstitution acetic acid.

Synthesis of Tertiary Benzylic Nitriles via Nickel-Catalyzed Markovnikov Hydrocyanation of α-Substituted Styrenes

The Markovnikov hydrocyanation of α-substituted styrenes enables the synthesis of tertiary benzylic nitriles under nickel catalysis. The Lewis-acid-free transformation features an unprecedented functional groups tolerance, including the-OH and-NH2 groups. A broad range of tertiary benzylic nitriles were obtained in good to excellent yields. In addition, an asymmetric version of this reaction was preliminarily investigated.

Diphenyl-aminopyrimidine compound for inhibiting kinase activity

The invention relates to a diphenyl-aminopyrimidine compound with an inhibiting function on protein tyrosine kinase, a pharmaceutical composition containing the diphenyl-aminopyrimidine compound, andpreparation and application of the diphenyl-aminopyrimidine compound, in particular to a compound shown as the formula (I) and pharmaceutically acceptable salt or crystal forms or prodrugs or metabolin or aquo-complex or solvate or isotope derivatives thereof, wherein R1, R2, R5, R6, R7, R8 and W are defined as the description. The compound can be used for treating ALK-mediated cancer related symptoms, such as non-small cell lung cancer or breast cancer or neural tumors or esophagus cancer or soft tissue cancer or lymphoma or leukemia. The formula is shown in the specification.

A tandem annulation with a [1,3]-hydride transfer as the key step leading to isochromans

An unprecedented method that enables the direct coupling of an α-C-H bond in alcohols with 2-arylacetaldehydes through a [1,3]-hydride transfer ([1,3]-HT) of oxocarbenium ions catalyzed by a Lewis acid has been developed. The redox neutral preparation of

Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities

17β-Hydroxysteroid dehydrogenase type 2 (17β-HSD2) is responsible for the oxidation of the highly active estradiol (E2) and testosterone (T) into the less potent estrone (E1) and Δ4-androstene-3,17-dione (Δ4-AD), respectively. As 17β-HSD2 is present in bones and as estradiol and testosterone are able to induce bone formation and repress bone resorption, inhibition of this enzyme could be a new promising approach for the treatment of osteoporosis. Herein, we describe the design, the synthesis and the biological evaluation of 24 new 17β-HSD2 inhibitors in the 5-substituted thiophene-2-carboxamide class. Structure-activity and structure-selectivity relationships have been explored by variation of the sulfur atom position in the central core, exchange of the thiophene by a thiazole, substitution of the amide group with a larger moiety, exchange of the N-methylamide group with bioisosteres like N-methylsulfonamide, N-methylthioamide and ketone, and substitutions at positions 2 and 3 of the thiophene core with alkyl and phenyl groups leading to 2,3,5-trisubstituted thiophene derivatives. The compounds were evaluated on human and mouse enzymes. From this study, a novel highly potent and selective compound in both human and mouse 17β-HSD2 enzymes was identified, compound 21 (IC 50(h17β-HSD2) = 235 nM, selectivity factor toward h17β-HSD1 = 95, IC50 (m17β-HSD2) = 54 nM). This new compound 21 could be used for an in vivo proof of principle to demonstrate the true therapeutic efficacy of 17β-HSD2 inhibitors in osteoporosis. New structural insights into the active sites of the human and mouse enzymes were gained.

SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologi

NEW COMPOUNDS

The present invention encompasses compounds of general formula (1) wherein A, B, X, R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and t

CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGD2 receptors described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.